← Leaderboards
Miguel Angel Villalona
Ohio State University
$9,621,601
Attributed
$16,324,599
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,324,599 · 13
By mechanism
UM1$7,453,070 · 1
R01$4,077,072 · 2
R21$1,887,984 · 3
N01$1,089,680 · 2
M01$737,329 · 2
T32$534,072 · 1
Top collaborators
- Jianhua Yu4 shared
- Steven M. Devine3 shared
- Primo N Lara3 shared
- A. Dimitrios Colevas2 shared
- Heinz Josef Lenz2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Michael A Caligiuri$65,062,344
- Ramiro Garzon$6,835,986
- Louis M Mansky$15,115,622
- Amina Abdul-Aziz$737,831
- Sydney Fobare$195,812
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchMalignant NeoplasmsClinical TrialsHuman SubjectTumorSafetyHuman Therapy EvaluationMolecular TargetSignal TransductionTumor TissueBiopsyDoseResourcesIn VivoDrug Screening /EvaluationNeoplasm /Cancer ChemotherapyDosageClinicIn VitroCancer PatientCessation Of LifeCombination ChemotherapyTreatment StrategyMitomycin C
Grant awards (35)
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors$562,792
R01 · FY2025 · CA · contact PI
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$1,594,203
UM1 · FY2023 · CA · contact PI
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors$358,924
R01 · FY2023 · CA · contact PI
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors$253,630
R01 · FY2023 · CA · contact PI
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors$620,673
R01 · FY2022 · CA · contact PI
Developmental Cancer Therapeutics$61,763
P30 · FY2022 · CA · contact PI
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$5,651,467
UM1 · FY2020 · CA · contact PI
A Correlative Biomarker Analysis for A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory NHL$207,400
UM1 · FY2020 · CA · contact PI
Targeting Somatic Homologous Recombination in Solid Tumors$489,114
R01 · FY2014 · CA · contact PI
Training Hematology and Oncology Fellows in Clinical Research$204,934
T32 · FY2014 · CA · contact PI
Targeting Somatic Homologous Recombination in Solid Tumors$478,981
R01 · FY2013 · CA · contact PI
Training Hematology and Oncology Fellows in Clinical Research$196,169
T32 · FY2013 · CA · contact PI
Targeting Somatic Homologous Recombination in Solid Tumors$516,618
R01 · FY2012 · CA · contact PI
Training Hematology and Oncology Fellows in Clinical Research$132,969
T32 · FY2012 · CA · contact PI
Targeting Somatic Homologous Recombination in Solid Tumors$522,236
R01 · FY2011 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$104,949
N01 · FY2011 · CA · contact PI
Targeting Somatic Homologous Recombination in Solid Tumors$274,104
R01 · FY2010 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$106,871
N01 · FY2010 · CA · contact PI
TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8472$754,737
N01 · FY2009 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$123,123
N01 · FY2009 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS-261622007$0
N01 · FY2006 · CM · contact PI
Biomodulation of capecitabine by docetaxel in non-small*$306,475
R21 · FY2005 · CA
TNF Blockade in Pancreatic Cancer Patients$332,638
R21 · FY2004 · CA
Biomodulation of capecitabine by docetaxel in non-small*$306,475
R21 · FY2004 · CA
TNF Blockade in Pancreatic Cancer Patients$332,638
R21 · FY2003 · CA
Phase II randomized trial of CPT-11 and Mitomycin C$281,570
R21 · FY2003 · CA
Phase II randomized trial of CPT-11 and Mitomycin C$328,188
R21 · FY2002 · CA
PHASE I STUDY OF SEQUENTIAL CPT 11 &MITOMYCIN C$234,837
M01 · FY2002 · RR
PHASE I STUDY OF SEQUENTIAL CPT 11 &MITOMYCIN C$234,837
M01 · FY2002 · RR
TRANSLATIONAL RESEARCH IN LUNG CANCER$162,000
K01 · FY2002 · CA
PHASE I STUDY OF SEQUENTIAL CPT 11 &MITOMYCIN C$234,837
M01 · FY2001 · RR
TRANSLATIONAL RESEARCH IN LUNG CANCER$160,909
K01 · FY2001 · CA
TRANSLATIONAL RESEARCH IN LUNG CANCER$160,720
K01 · FY2000 · CA
PHASE I STUDY OF SEQUENTIAL CPT 11 &MITOMYCIN C$16,409
M01 · FY2000 · RR
PHASE I STUDY TO DETERMINE THE SAFETY OF ECTEINASCIDIN-743$16,409
M01 · FY2000 · RR